GET DAILY SIGNALSKeros Therapeutics (KROS) Q3 2026 Earnings Preview: Pipeline Focus After +14% Gain
Key Takeaways
- Keros Therapeutics is expected to report third quarter 2026 results around November 4–5, with consensus calling for a net loss of approximately $0.96 per share.
- Analysts project revenue of roughly $14.76 million for the quarter, compared with $14.26 million in the same period a year earlier.
- The company has beaten consensus earnings per share estimates in four of its last eight quarters, but missed in its most recent report.
- As a clinical-stage biopharmaceutical company, Keros' quarterly results are often less significant to investors than pipeline updates, trial data, and its cash runway.
- For more context on KROS, readers can explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
- Investors seeking additional market signals may also want to explore Tickeron's Trending AI Robots for automated, data-driven trade ideas.
Why This Earnings Report Matters
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and musculoskeletal disorders. Its quarterly financials are typically less about profitability and more about execution and capital management. The upcoming report matters because it offers investors a window into the company's research and development spending, operating expenses, and cash position. Keros has delivered uneven recent results, missing consensus estimates in its last reported quarter while beating in four of the past eight. With no product revenue at scale yet, the market will watch closely for any commentary on clinical progress, trial timelines, and whether the company's cash balance remains sufficient to fund its programs into meaningful milestones. I also checked this using Tickeron’s AI Screener to see how KROS compares to others in the industry.
What Analysts Are Expecting
Wall Street consensus points to a net loss of approximately $0.96 per share for the third quarter of 2026, with revenue estimated near $14.76 million. That compares with a loss of $0.18 per share on revenue of $14.26 million in the same period a year ago. In its most recent quarter, Keros posted a loss of $1.45 per share, missing consensus estimates. Investors will likely focus less on top-line revenue and more on the trajectory of research and development costs, general and administrative expenses, and the company's reported cash position, which stood near $257.6 million as of mid-2026. Guidance on expected spending and cash runway will be a key area of attention.
Recent Performance and Market Sentiment
Sentiment heading into the third quarter report remains cautious. KROS shares have climbed roughly 14% since the company's last earnings release in early August 2026, suggesting some investor optimism has returned despite the recent earnings miss. However, clinical-stage biotech names can be especially sensitive to earnings events because investors interpret even modest changes in spending guidance or cash runway as signals about future funding needs and trial momentum. Key risk factors include the pace of research and development expenses, any indication of accelerated cash burn, and the absence of near-term revenue catalysts. A surprise in either direction on spending or pipeline commentary could drive outsized share-price moves.
What to Watch Going Forward
Looking past the headline figures, investors will be watching several forward-looking indicators. First is cash runway. As a pre-revenue-stage company, Keros' most important near-term question is how long its existing cash can fund operations before additional capital may be required. Any update on expected quarterly operating expenses or cost-containment efforts will be closely scrutinized.
Second is pipeline execution. Progress on clinical trials, enrollment timelines, and upcoming data readouts often matter more than the income statement for a clinical-stage biopharmaceutical company. Commentary from management on development milestones can shape the stock's direction more than the reported loss per share.
Third is the broader biotech funding environment. Market conditions for capital raises and partnership activity can influence both sentiment and strategic options. Investors should monitor any guidance revisions, changes in operating expense trends, and announced collaborations or financing arrangements that could extend the company's runway or validate its pipeline.
AI Tools in Biotech Research
In my analysis of names like KROS, I often turn to Tickeron's AI Screener for quick comparisons across the biotech sector. It helps filter technical patterns, fundamentals, and AI signals without manual effort, giving a structured view alongside traditional research. This approach has been useful for spotting relative strength or weakness in similar clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for KROS turns negative, indicating new downward trend
KROS saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 77 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 225 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 187 of 226 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.819) is normal, around the industry mean (3.051). P/E Ratio (-3.363) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology
Advertisement